MedWorm provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest medical blog items that have been tagged with 'effexor xr'. Sat, 03 Sep 2011 02:51:02 +0100 http://www.medworm.com/index.php?rid=4098464&cid=t_153550_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FIAF1KmZPK2w%2F Good morning, everyone. The end of the week is rapidly approaching and that usually means one thing - daydreaming about weekend plans. We expect to catch up on a few chores, but will spend most of our time entertaining the shortest of short people with a little bowling and ice cream, and a trip to the book store. What about you? A drive in the country to watch the leaves change? Toss a football? Pick a pumpkin? Walk your own official mascots? Whatever you do, have a good time and be safe. See you soon… EMA Revises Stance On Genzyme’s Fabrazyme (Reuters) Wyeth Must Disclose Earlier Effexor XR Patent Settlements (New Jersey Law Journal) Amgen Exec Retires And Gets $400K Consulting Deal (SEC filing) FDA Adds Heart Warning To HIV Drug Combo (Associated Press) Roche And Biogen End D... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=4098464 Fri, 22 Oct 2010 12:06:06 +0100 4098464 http://www.medworm.com/index.php?rid=3710798&cid=t_153550_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FPlw3NtaReH4%2F Top of the morning to you. Another balmy day here on the Pharmalot corporate campus, where an usual quiet has set in now that the short people are busy with their summer activities. We are keeping busy, of course, sifting through documents. And you? Projects and meetings beckon, no doubt. To cope, please join us for a cup of stimulation and a peek at a few interesting items. Have a nice day, everyone… Bayer Drops One Patent Infringement Case Over Yaz (Reuters) Novartis Can’t Force Alcon Merger (PharmaTimes) Teva Gets FDA OK For Generic Effexor XR (Reuters) UK’s NICE Reverses Decision On Rheumatoid Arthritis Meds (PharmaTimes) Speeding Clinical Trial Recruitment With E-records (Outsourcing Pharm) Abbott Puts Solvay Flu Biz Up For Sale (The Wall Street Journal) Taro Pharma ... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=3710798 Tue, 29 Jun 2010 11:45:35 +0100 3710798 http://www.medworm.com/index.php?rid=3185620&cid=t_153550_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FcXg3NJ5cmOI%2F Scott Reuben is on the hook for nearly $300,000 for faking research he conducted on various meds. The former chief of acute pain at Baystate Medical Center in Springfield, Ma., sought and received research grants from Pfizer and other drugmakers but never performed the studies. He fabricated patient data and submitted info to anesthesiology journals that unwittingly published it. Reuben must also pay $16,000 in restitution to Wyeth, which is now owned by Pfizer, and $49,375 to Merck (see documents here). You may recall that, last week, federal prosecutors filed a health care fraud charge against Reuben, who is accused of faking research for a dozen years in published studies suggesting Vioxx and Celebrex offered benefits after surgery. Reuben agreed to plead guilty in exchange for a recomm... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=3185620 Tue, 19 Jan 2010 13:07:40 +0100 3185620 http://www.medworm.com/index.php?rid=1537900&cid=t_153550_109_f&fid=34750&url=http%3A%2F%2Fpsychcentral.com%2Fblog%2Farchives%2F2008%2F06%2F23%2Fwyeths-dr-phil-ninan-on-pristiq%2F Pages: 1 2 Next »     Single Page This is the inaugural entry of a new occasional feature we’ll have here on World of Psychology, On the Couch with Dr. John Grohol. These entries will be interviews with various movers and shakers in the world of psychology, mental and behavioral health, and psychiatry. The schedule is to do at least one a month, so if there’s someone you’d like to see interviewed, please drop us a note! Last Wednesday, I had the chance to sit down and talk to Dr. Phil Ninan, the Vice President of Wyeth’s Medical Affairs, Neuroscience on the telephone about their newest antidepressant medication, Pristiq. Pristiq is a “chemical cousin” of Wyeth’s existing successful antidepressant, Effexor (and its descendants... World of Psychology blogs http://www.medworm.com/rss/comments.php?id=1537900 Mon, 23 Jun 2008 18:38:20 +0100 1537900 http://www.medworm.com/index.php?rid=1472695&cid=t_153550_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F299264877%2F New York psychiatrist Jeff Lieberman has heard J&J’s sales pitch for its new Invega schizophrenia drug, but he’s not too impressed. The problem, he tells Dow Jones, is that Ivega isn’t much different than one of J&J’s best-selling drugs, the antipsychotic Risperdal. In late June, Risperdal is scheduled to lose patent protection, clearing the way for cheaper generics, which could further diminish Invega sales, already characterized as a disappointment by J&J. “I don’t think they have a strong case to make,” Lieberman, chairman of the psychiatry department at Columbia University’s medical school, tells the news service. “It’s basically a me-too drug, and the company hasn’t done the studies that would be required... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1472695 Tue, 27 May 2008 18:43:28 +0100 1472695 http://www.medworm.com/index.php?rid=1391296&cid=t_153550_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F275485979%2F Facing a pipeline that can’t compensate for the looming patent expirations of its biggest products, Wyeth hopes to generate revenue with a special introductory offer for it Pristiq antidepressant - when the pill launches next month, the price will be up to 20 percent less than the cost of Wyeth’s existing Effexor antidepressant. Pristiq is, essentially, a revamped version of Effexor XR, a $3.8 billion seller that loses patent protection in 2010, if not sooner. And so Wyeth’s senior vp, Joe Mahady, told analysts that Pristiq will sell for a flat $3.41 per pill for both the mid-range and high-dose versions, according to Dow Jones. By comparison, the 150 mg version of Effexor XR costs $4.19 each, according to drugstore.com. That works out to a 22 percent difference. The site... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1391296 Tue, 22 Apr 2008 15:51:28 +0100 1391296 http://www.medworm.com/index.php?rid=1108700&cid=t_153550_97_f&fid=35050&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmaGazette%2F%7E3%2F203604650%2Fsun_pharm_may_best_wyeth_with.html Wyeth Pharmaceuticals Inc. may have thought that their biggest drug, Effexor XR, was safe from competition for a while but Sun Pharmaceuticals may be cutting into the revenue pie. Wyeth holds the patent on Effexor XR capsules until July 2010 which means no other company can sell a generic version until that time. However, Sun may have found a way around it by producing its generic version of Effexor in tablet form. While both the capsule and tablet have the exact same ingredients, the simple change in pill format should allow Sun to get around patent protection when Wyeth's patent on the drug's main ingredient, venlafazine, expires in June 2008.Wyeth has implied that it expects little impact from the generic pills as they are unlikely to get FDA certification as the exact... PharmaGazette blogs http://www.medworm.com/rss/comments.php?id=1108700 Thu, 20 Dec 2007 18:00:35 +0100 1108700 http://www.medworm.com/index.php?rid=1107125&cid=t_153550_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F203403450%2F Bernard Poussot has many challenges as he gets ready to succeed Bob Essner as Wyeth ceo. High on that list is Effexor XR, the big-selling antidepressant. The pill’s exclusivity is being threatened by Sun Pharmaceutical, an Indian generics maker, which is seeking FDA approval to sell a version with the same active ingredient, but with an important difference - in tablet, not capsule form, the Associated Press writes. FDA approval could come as early as June, when patent protection for Effexor’s active ingredient, venlafaxine, runs out, while the patent on the capsule formation doesn’t expire until later. So as the AP points out, Sun’s different formulation should allow it to sidestep Wyeth’s patent rights, and grab up to 15 percent of Effexor XR’s market ... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1107125 Thu, 20 Dec 2007 13:20:04 +0100 1107125 http://www.medworm.com/index.php?rid=972758&cid=t_153550_97_f&fid=35050&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmaGazette%2F%7E3%2F173969762%2Feffexor_xr.html (extended release) by Wyeth Pharmaceuticals Inc. is the 6th best selling prescription medication in the U.S according to Drug Topics' Top 200 Brand Name Drug by Retail Dollars in 2006.It has been approved to treat major depression, panic disorder, generalized anxiety disorder and social anxiety disorder. Effexor XR is taken once a day and comes in three strength 35.7 mg, 75 mg and 150 mg. Effexor (Venlafaxine) is an antidepressant of the serotonin-norepinephrine reuptake inhibitor (SNRI) class and has been in use since 1993. It works by blocking the transporter "reuptake" proteins for key neurotransmitters affecting mood thus leaving more active neurotransmitters in the synapse. The half-life of venlafaxine is short and patients can experience withdrawal symptoms a... PharmaGazette blogs http://www.medworm.com/rss/comments.php?id=972758 Tue, 23 Oct 2007 20:15:19 +0100 972758